Filed in archive
Studies
, Treatment
by Gloria Gamat on March 8, 2006
As reported by Hilary Overton, Christine Reynet, and colleagues of the biotechnology company (OSI)Prosidion, the team found that so-called oleoylethanolamide, a naturally occurring lipid-signaling agent earlier shown to reduce food intake and weight gain in rats, can exert its effects through the G protein-coupled receptor (GPCR) GPR119.
A large proportion of all drugs sold today target GPCRs, protein "switches" that recognize and translate signals into cellular responses. Found predominantly in the pancreas and digestive tract in humans and mice, as well as in the rodent brain, the function of GPR119 had previously remained mysterious.
After screening a proprietary library of small molecules including several hundred thousand compounds for their ability to activate GPR119, the researchers then identified one such chemical, known only as PSN632408. PSN632408 had no effect on the distantly related cannabinoid receptors, which are the targets of the candidate obesity drug rimonabant, the team reported.
Just ignore the technicalities. Simply put, if and when this study passed human clinical trials, it would mean popping a pill to combat obesity, weight gain and other metabolic disorders. Isn't that truly exciting?
Source: [EurekAlert]
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/17934
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for obesity and (related metabolic disorders) receptor, targeted by experimental drug:
|
Rating: 8.00 out of 1 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
